GlassScriptPhysician profile
Lori A Woods
NPI 1629054655
$6,582.25
in general payments reported to CMS, 2019-2025
20 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $511 · 2022: $841 · 2023: $993 · 2024: $2,053 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,024 · Travel and Lodging: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.25 |
| Travel and Lodging | $1,205.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,344.23 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $923.94 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $666.03 | 2021-2025 | Nucala, Trelegy Ellipta |
| Alk-Abello, INC | $517.93 | 2021-2025 | Ragwitek, Odactra, Grastek |
| Jazz Pharmaceuticals INC. | $419.10 | 2021-2025 | |
| Optinose US, INC. | $399.85 | 2021-2025 | |
| Genzyme Corporation | $337.68 | 2023-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $219.51 | 2024-2025 | Lumryz |
| Aerin Medical INC. | $176.51 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $153.36 | 2021-2025 | Airsupra, Tezspire |
| Kaleo, INC. | $118.21 | 2021-2024 | Auvi-Q |
| Fisher & Paykel Healthcare INC | $69.44 | 2022-2024 | Fisher & Paykel Healthcare |
| Axsome Therapeutics, INC. | $58.57 | 2023-2024 | Sunosi |
| Ars Pharmaceuticals Operations, INC. | $41.70 | 2025 | Neffy |
| Uswm, LLC | $33.09 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.38 | 2021 | |
| Phadia US INC. | $21.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2024 | Eohilia |
| Merck Sharp & Dohme LLC | $18.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.